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Abstract
OBJECTIVES: Annual testing using either a high-sensitivity guaiac fecal occult blood test (HS-
gFOBT) or a fecal immunochemical test (FIT) is recommended for screening average-risk people 
for colorectal cancer. We compared the performance characteristics of the HS-gFOBT Hemoccult 
II SENSA and two FITs (InSure FIT and OC FIT-CHEK) for detecting advanced colorectal 
neoplasia.
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METHODS: The study included 1,006 asymptomatic patients, aged 50–75 years, who were 
scheduled to receive a screening colonoscopy at gastroenterology practices in the Minneapolis and 
Indianapolis metropolitan areas. Each participant was asked to complete all three stool tests before 
their colonoscopy. Each test’s performance characteristics were evaluated using the screening 
colonoscopic results as the reference standard.
RESULTS: Sensitivity for detecting advanced colorectal neoplasia was highest for InSure FIT 
(26.3%, 95% confidence interval (CI) 15.9–40.7), followed by OC FIT-CHEK (15.1%, 95% CI 
6.7–26.1) and Hemoccult II SENSA (7.4%, 95% CI 1.9–17.0). InSure FIT was statistically 
significantly more sensitive than both OC FIT-CHEK (absolute difference in sensitivity=11.2%, 
95% CI 0.4–24.2) and Hemoccult II SENSA (difference in sensitivity=18.9%, 95% CI 10.2–32.6). 
Specificities were relatively high for all tests (between 96.8% and 98.6%).
CONCLUSIONS: Our results suggest that some FITs are more sensitive than the HS-gFOBT 
Hemoccult II SENSA, but these results need to be confirmed in larger asymptomatic populations. 
Comparisons between the FITs examined in this study and other FITs are needed to determine the 
best tests for population screening.
INTRODUCTION
Colorectal cancer is a leading cause of cancer-related morbidity and mortality (1,2). There 
are several recommended screening options for the population aged ≥50 years at average 
risk for colorectal cancer, including colonoscopy every 10 years or annual fecal occult blood 
testing (FOBT) using either a high-sensitivity guaiac FOBT (HS-gFOBT) or a fecal 
immunochemical test (FIT) (3–5). Colonoscopy has higher sensitivity and specificity than 
FOBT for detecting advanced colorectal neoplasia; however, using colonoscopy to screen 
the average-risk population has several disadvantages, including higher cost, increased risk 
of complications, and limited capacity of the health-care system to perform colono scopies. 
In addition, many patients prefer FOBT to colonoscopy; some patients may not be screened 
at all unless they are offered a stool blood test as an alternative to colonoscopy (6–10).
Randomized trials have shown that annual or biennial testing using the traditional gFOBT 
reduces colorectal cancer incidence and mortality (11–15). However, the sensitivity and 
specificity of traditional gFOBTs is relatively low (16–19). Guaiac FOBTs detect the heme 
component of hemoglobin molecules because of the pseudoperoxidase activity of heme, 
which converts guaiac to a blue color when a developer is added. The newer version of the 
guaiac-based test (HS-gFOBT) added an enhancer to the developer to permit detection of 
lower levels of peroxidase activity and thereby increase sensitivity, although evidence for 
higher sensitivity is limited (16,20). A limitation of gFOBTs is that they can produce false-
positive or false-negative results with certain foods, vitamins, or medications, so dietary 
restrictions are generally recommended before the test (3). In addition, three stool samples 
are recommended for gFOBTs, including the HS-gFOBT.
FIT is a newer type of FOBT that avoids some limitations of the gFOBT. FIT uses 
antibodies to detect the globin portion of human hemoglobin and does not require dietary 
restrictions (21). Additionally, some FITs require fewer samples. However, to our 
knowledge, only one study has directly compared the performance characteristics of a FIT 
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available in the United States with the performance characteristics of the HS-gFOBT 
Hemoccult II SENSA in an asymptomatic screening population with endoscopic follow-up 
(16).
To add to the evidence on FOBT performance characteristics for detection of advanced 
colorectal neoplasia, we conducted a study in an asymptomatic screening population. 
Specifically, we compared the performance characteristics of the HS-gFOBT Hemoccult II 
SENSA with the performance characteristics of two FITs (OC FIT-CHEK and InSure FIT), 
using a screening colonoscopy completed after the stool tests were collected as the reference 
standard for determining the presence of advanced colorectal neoplasia.
METHODS
Participant recruitment
Participants in this study, the Study of In-home Tests for Colorectal Cancer (SIT), were 
recruited by two clinical sites: the University of Minnesota (UMN) and Indiana University 
(IU). UMN participants were recruited from clinics in the Minneapolis, Minnesota 
metropolitan area (Minnesota Gastroenterology and Park Nicollet Health Services). IU 
participants were recruited from Indiana University Health clinics in the Indianapolis, 
Indiana metropolitan area. Participants were enrolled between May 2011 and July 2014. All 
colonoscopies were performed not later than September 2014. The study protocol was 
approved by the Institutional Review Boards of the Centers for Disease Control and 
Prevention, Battelle Memorial Institute, UMN, and IU.
Participant eligibility criteria
Asymptomatic patients aged 50–75 years who were scheduled to have a colonoscopy for 
colorectal cancer screening were eligible. Patients were ineligible if they were having a 
colonos-copy because of bleeding or other symptoms or as a follow-up to a positive or 
abnormal flexible sigmoidoscopy, double-contrast barium enema, computed tomographic 
colonography, or FOBT. Patients were also ineligible if they had >1 episode of rectal 
bleeding in the past 6 months, a personal history of colorectal cancer or colorectal polyps, a 
positive FOBT in the past 12 months, a colonoscopy within the past 5 years, a prior colon 
resection or other colon/rectal surgery, a history of inflammatory bowel disease, a personal 
or family history of familial adenomatous polyposis or hereditary nonpolyposis colorectal 
cancer, were currently taking anticoagulant medication, or were not able to read English. To 
increase statistical power, most participants enrolled were aged 60–75, as older individuals 
are more likely to have colorectal neoplasia.
Fecal occult blood tests
Clinical site staff asked participants to complete sample collection for three types of FOBTs 
(one HS-gFOBT and two FITs) prior to their colonoscopy. The HS-gFOBT was the 
Hemoccult II SENSA test (manufactured by Beckman Coulter, Brea, CA), which required 
testing of three stool samples collected on different days. The FITs were the two-sample test 
InSure FIT (manufactured by Enterix, Edison, NJ), which required testing of two stool 
samples from different days, and the one-sample test OC FIT-CHEK (marketed by 
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Polymedco, Cortlandt Manor, NY). For the two FITs, the cutoff values for positivity were 
the standard values used in the United States, as this study was designed to look at the 
performance characteristics of these tests in usual clinical practice. For InSure FIT, the 
cutoff value for positivity was 50 μg hemoglobin (Hb)/gram (g) of feces. For OC FIT-
CHEK, the cutoff value was 20 μg Hb/g of feces. For each test, only one sample needed to 
be positive for the test to be considered positive.
Participants were randomly assigned to one of six equal-sized groups; each group completed 
the three FOBTs in a different order. After each FOBT was completed, the participant 
mailed it to a central laboratory for analysis (Hemoccult II SENSA to Emory University 
Hospital laboratory, Atlanta, GA; InSure FIT to Quest Diagnostics, Tucker, GA; and OC 
FIT-CHEK to Kaiser Permanente Regional Laboratory, Atlanta, GA). Participants were sent 
a monetary incentive of $100 for study participation.
Colonoscopy and pathology
A colonoscopy was performed by the clinic where the patient was recruited. Two 
pathologists at each clinic independently reviewed the pathology specimens from the 
colonoscopies. If the two pathologists did not agree, the pathology specimens were reviewed 
by a third pathologist.
Our primary definition of advanced colorectal neoplasia included any of the following 
colonoscopy findings confirmed by pathology: tubular adenoma with a size ≥10 mm, sessile 
serrated polyp with dysplasia, villous adenoma, tubulovillous adenoma, adenoma with high-
grade dysplasia, or invasive carcinoma.
Study population
In total, 3,985 patients were screened for eligibility and invited to enroll; 1,382 patients met 
initial eligibility criteria and signed a consent form. Of these, 1,095 (79.2%) participants 
completed the colonoscopy, the gFOBT, and at least one FIT. The test result for the gFOBT 
or FIT was considered invalid if the time from sample collection to laboratory analysis was 
greater than recommended by the manufacturer (>14 days for Hemoccult II SENSA or 
InSure FIT or >15 days for OC FIT-CHEK). Participants were excluded if they did not have 
a valid test result for the gFOBT and at least one of the two FITs, if the time from the first 
FOBT sample collection date to the colonoscopy was >100 days, or if tissue was removed 
during the colonoscopy but they did not have a second pathology review. In addition, unless 
advanced colorectal neoplasia was found, participants were excluded if bowel preparation 
was rated as inadequate or poor or if the cecum was not visualized. After these exclusions, 
1,006 (72.8%) participants remained in the primary analysis. Because of the exclusion 
criteria, all these participants had completed the Hemoccult II SENSA test. A total of 947 
also had a valid OC FIT-CHEK test result and 987 had a valid InSure FIT test result; 928 
(67.1%) participants had valid results for all three stool tests.
Statistical analysis
Positivity rates and performance measures were calculated for each FOBT. Performance 
measures included sensitivity, specificity, positive predictive value, and likelihood ratios. To 
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ensure that the correlated nature of the three FOBT tests was accounted for in the variability 
of the estimates and comparisons, bias-corrected estimates of performance measures were 
calculated from 2,000 bootstrap samples (22) drawn from the original sample using the 
bootstrap function in R (23). Point estimates and pairwise differences in sensitivity and 
specificity were calculated for each FOBT type and across covariate subgroups within each 
FOBT type. Ninety-five percent confidence intervals (CIs) were calculated using the 
adjusted bootstrap percentile method. Differences were considered statistically significant if 
the 95% CI for the difference estimate did not include zero. For subgroup analyses with <10 
advanced colorectal neoplasia cases or with zero counts in a cell, CIs were not calculated for 
differences. Statistical analysis was performed with SAS software version 9.3 (SAS 
Institute, Cary, NC) and R version 3.2.5 (R Foundation for Statistical Computing, Vienna, 
Austria).
RESULTS
Demographic and medical history characteristics of study participants are presented in Table 
1. To increase statistical power, most participants enrolled were aged 60–75 years (61.5%). 
Participants were slightly more likely to be female (54.5%). Participant-reported race was 
primarily white (87.0%); 10.6% were black or African American, and few participants were 
Hispanic or Latino (2.5%). Most participants (86.8%) did not report a first-degree family 
history of colorectal cancer. Most participants (73.3%) had a prior colorectal cancer 
screening test (Table 1).
Advanced colorectal neoplasia was found on colonoscopy in 5.5% of participants (N =55), 
including two invasive cancers (Table 2). The other types of advanced findings are listed in 
Table 2. One of the cancer cases had positive Hemoccult II SENSA and InSure FIT tests but 
a negative OC FIT-CHEK test. The other cancer case was negative for all three stool tests. A 
total of 344 participants had one or more adenomas detected on colonoscopy for an adenoma 
detection rate (ADR) of 34.2%. The ADR was 40.4% for males and 29.0% for females. For 
the UMN site, the ADR was 38.5% for males and 26.5% for females. For the IU site, the 
ADR was 49.4% for males and 37.6% for females (data not shown).
Stool test performance characteristics for advanced colorectal neoplasia are presented in 
Table 3. Of the three stool tests, InSure FIT had the highest positivity (4.5%) and the highest 
sensitivity for advanced colorectal neoplasia (26.3%, 95% CI, 15.9–40.7) but also had the 
lowest specificity (96.8% (95% CI, 95.5–97.8)). In contrast, the Hemoccult II SENSA had 
the lowest positivity (1.7%) and the lowest sensitivity (7.4%, 95% CI, 1.9–17.0) but the 
highest specificity (98.6%, 95% CI, 97.7–99.2). Differences between Hemoccult II SENSA 
and InSure FIT were statistically significant for both sensitivity (difference=18.9%, 95% CI, 
10.2, 32.6) and specificity (difference=−1.8%, 95% CI,−3.3, −0.7). For the OC FIT-CHEK, 
estimates for performance characteristics were between the values for InSure FIT and 
Hemoccult II SENSA (positivity of 3.0%, sensitivity of 15.1% (95% CI, 6.7–26.1), 
specificity of 97.8% (95% CI, 96.6–98.6)). The difference in sensitivity between OC FIT-
CHEK and InSure FIT was statistically significant (difference=11.2%, 95% CI, 0.4, 24.2).
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Stool test performance characteristics for serrated lesions of any size (sessile serrated 
polyps, sessile serrated polyps with dysplasia, or traditional serrated adenomas) are 
presented in Table 4. Sensitivity for serrated lesions was low for all three stool tests, ranging 
from 2.6% to 5.2%.
We also examined sensitivity and specificity among subgroups of participants, although 
statistical power was limited. Results were similar to the overall results when we excluded 
patients with a known family history of colorectal cancer in first-degree relatives or patients 
with a recent colorectal cancer screening test (colonoscopy within the past 10 years, double-
contrast barium enema, computed tomographic colonography, or sigmoidoscopy within the 
past 5 years). Results were also similar when we performed analyses in the 928 patients with 
valid results for all three stool tests (see Supplementary Table S1 online). There were no 
statistically significant differences in sensitivity or specificity when the population was 
stratified by age (50–59 vs. 60–75), gender, or race (African-American vs. white), although 
the comparisons of OC FIT-CHEK sensitivity and specificity by race, Hemoccult II SENSA 
sensitivity by age and race, and InSure FIT sensitivity by race were not possible due to small 
counts in some cells.
There were no statistically significant differences in sensitivity or specificity when the 
population was stratified by the time from stool collection to laboratory analysis (≤7 days vs. 
≥8 days) or by season of stool collection (May–September vs. October–April). Positivity 
rates were lower for each stool test for the hotter months of May–September compared with 
October–April, but this difference was only statistically significant for InSure FIT.
When we expanded the definition of advanced colorectal neoplasia to include sessile 
serrated polyps with a size ≥10 mm (N =15), the sensitivity for each stool test was reduced 
(5.8% for Hemoccult II SENSA, 11.8% for OC FIT-CHEK, 20.5% for InSure FIT). The 
sensitivity for each stool test was further reduced when we also added ≥3 conventional 
adenomas of any size (N =33) to this definition of advanced colorectal neoplasia (3.9% for 
Hemoc-cult II SENSA, 11.0% for OC FIT-CHEK, 16.1% for InSure FIT).
DISCUSSION
In this study, we compared the test performance characteristics of the HS-gFOBT 
Hemoccult II SENSA with the performance characteristics of two FITs in an asymptomatic 
population undergoing screening colonoscopy. Specificities were relatively high for all of 
the tests (between 96.8% and 98.6%). Sensitivity for advanced colorectal neoplasia was 
higher for the two FITs than for the HS-gFOBT Hemoccult II SENSA, although none of the 
stool tests had a sensitivity for advanced colorectal neoplasia >30%. InSure FIT had the 
highest sensitivity (26.3%), followed by OC FIT-CHEK (15.1%) and Hemoccult II SENSA 
(7.4%).
We could only find one previous study of InSure FIT that compared FIT results, whether 
positive or negative, with colonoscopic results. In a small study of 304 patients, of whom 
approximately one-third had a personal history of colorectal neoplasia, the sensitivity for 
advanced colorectal neoplasia was 36% (95% CI, 18–53), slightly higher than we found, 
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although within our 95% confidence bounds (24). The specificity was 92% (95% CI, 89–
96), lower than we found and outside our 95% confidence bounds.
There have been several studies of the OC FIT-CHEK family of FITs. This family of FITs 
includes tests with different names (such as OC-Micro, OC-Sensor, and OC-SENSA Micro) 
manufactured by Eiken Chemical Company (Tokyo, Japan) and marketed in the United 
States by Polymedco. In our study, we tested one stool sample using OC FIT-CHEK with a 
cutoff value for positivity of 20 μg Hb/g of feces, the cutoff value used in the United States. 
Other studies that have examined the one-sample OC FIT-CHEK (or comparable FIT tests 
with different names) at this cutoff value, and that used colonoscopy follow-up for all 
patients, have reported sensitivities for advanced colorectal neoplasia ranging from 24% to 
33%, somewhat higher than in our study and some exceeding our 95% confidence bounds 
(25–29). The specificity for FIT in these studies ranged from 95 to 97%, similar to the 
specificity in our study (25–29).
To our knowledge, only one previous study of asymptomatic patients has reported 
Hemoccult SENSA performance characteristics for advanced colorectal neoplasia with 
colonoscopy follow-up for all patients (20). In this study, the sensitivity for Hemoccult 
SENSA was 21% for advanced colorectal neoplasia, higher than our upper confidence 
bound, with a specificity of 97%, consistent with our confidence bounds. Another study 
followed up positive Hemoccult SENSA tests with colonoscopy and negative Hemoccult 
SENSA tests with sigmoidoscopy (16). They found an even higher sensitivity of 41% for 
large distal adenomas, with a much lower specificity than we found (91%).
For all three stool tests, we found that the sensitivity for serrated lesions was low. Our results 
are consistent with previous studies of serrated lesions (27,30,31). The low single-test 
sensitivity for ser-rated lesions may be due to the fact that serrated lesions are less likely to 
bleed (32). We were unable to examine the performance characteristics for large or advanced 
serrated lesions separately because of the small number of these lesions.
Results for a specific type of FIT cannot be generalized to other types of FIT. In our study, 
the two FITs appeared to differ in their performance characteristics, although only the 
difference in sensitivity was statistically significant. It should be noted that in our study the 
performance characteristics of each FIT were measured at different cutoff values for 
positivity and required different numbers of stool samples, as recommended by each FIT’s 
manufacturer and as used in standard clinical practice in the United States. However, even 
with the same cutoff value and number of samples, the performance characteristics of 
different FITs can vary (33,34). Factors that can affect performance characteristics, other 
than cutoffconcentration, include use of different antibodies that detect different epitopes 
and different immunoassay methods (21,33,35). Also, the buffers used in FITs can contain 
different preservatives, which can affect performance characteristics (34–36).
For any FOBT, including FITs, hemoglobin concentration may degrade during the time from 
sample collection to analysis, particularly at higher temperatures (33,35,37). Buffers are 
used to stabilize the hemoglobin during this time but can differ in their ability to stabilize 
hemoglobin (35). Some manufacturers have changed or are considering changing the buffer 
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to improve stability. Some, but not all, studies have found that time or temperature affects 
sensitivity or positivity rates (35,38–40). We excluded patients whose time from sample 
collection to laboratory analysis was greater than 14 or 15 days, as recommended by the 
manufacturer. We found no statistically significant differences in sensitivity or specificity by 
season when the stool was collected (May–September vs. October–April) or time from stool 
collection to laboratory analysis (≤7 days vs. ≥8 days), but our power was limited. We did 
find that positivity rates were lower for each stool test for the hotter months of May–
September, but the differences were only statistically significant for InSure FIT.
In our study, unlike many prior studies, the tests were conducted under conditions similar to 
those encountered in “real-world” clinical practice, including mailing of the tests to the 
laboratory without refrigeration during the mailing process. Some of the small number of 
previous studies found test sensitivities higher than we found. We do not know the reason for 
these differences, but these differences may have been due to chance or due to the conditions 
under which the tests were conducted.
Our study had several limitations. We did not have enough colorectal cancer cases to assess 
the sensitivity and specificity for cancer. Sensitivity for cancer would be expected to be 
higher than sensitivity for advanced colorectal neoplasia. We also had limited power to 
examine sensitivity for advanced colorectal neoplasia, particularly within subgroups. In 
addition, as in prior studies, we were only able to look at one-time screening instead of a 
program of annual stool test screening over multiple years. The one-time sensitivity for 
advanced colorectal neoplasia for the stool tests was relatively low, but sensitivity should be 
higher if the tests are performed annually as recommended by guidelines (5,41).
The 2016 US Preventive Services Task Force recommendations for colorectal cancer 
screening include either annual FIT or HS-gFOBT (5). In our study, one of the two FITs we 
examined, the InSure FIT, had significantly higher sensitivity than the other FIT (OC FIT-
CHEK) and the HS-gFOBT (Hemoccult II SENSA). The OC FIT-CHEK also had higher 
sensitivity than the Hemoccult II SENSA, although the difference was not statistically 
significant. Our results suggest that some FITs are more sensitive than the HS-gFOBT 
Hemoccult II SENSA, but these results need to be confirmed in larger asymptomatic study 
populations. Some FITs that are currently on the market do not have published literature to 
support their use. Comparisons between the two FITs examined in this study and other 
brands of FITs on the market are needed to determine which tests are most suitable for 
population screening for asymptomatic individuals.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Recommended colorectal cancer screening options include a high-sensitivity 
guaiac fecal occult blood test (HS-gFOBT) or a fecal immunochemical test 
(FIT).
✓ FITs vary in their performance characteristics.
✓ There is limited data comparing the performance characteristics of FITs to 
the HS-gFOBT.
WHAT IS NEW HERE
✓ One of the FITs studied (InSure FIT) had significantly higher sensitivity for 
advanced colorectal neoplasia than the other FIT (OC FIT-CHEK) and the 
HS-gFOBT (Hemoccult II SENSA).
✓ Our results suggest that some FITs are more sensitive than the HS-gFOBT 
Hemoccult II SENSA.
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Table 1.
Demographic and medical history characteristics of study participants (N=1006)
Characteristic Na (%)
Gender
 Male 458 (45.5%)
 Female 548 (54.5%)
Age at enrollment (years)
 50–54 160 (15.9%)
 55–59 227 (22.6%)
 60–75 619 (61.5%)
Race
 Black or African American 106 (10.6%)
 White 871 (87.0%)
 Otherb 24 (2.4%)
Ethnicity
 Hispanic or Latino 25 (2.5%)
 Not Hispanic or Latino 974 (97.5%)
Clinical site
 University of Minnesota 800 (79.5%)
 Indiana University 206 (20.5%)
Family history of colorectal cancer reported
 Yes 133 (13.5%)
 No 873 (86.8%)
Cancer screening history
 Any prior colorectal cancer screeningc
 Yes 726 (73.3%)
 No 265 (26.7%)
Prior FOBT (no positives in the past year)
 Yes 367 (36.8%)
 No 629 (63.2%)
Prior colonoscopy
 Never 392 (39.6%)
 >5–<10 years ago 292 (29.5%)
 ≥10 years ago 306 (30.9%)
Ever had a flexible sigmoidoscopy
 Yes 266 (26.8%)
 No 726 (73.2%)
Ever had a CT colonography
 Yes 5 (0.5%)
 No 994 (99.5%)
Ever had a double-contrast barium enema
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Characteristic Na (%)
 Yes 65 (6.7%)
 No 909 (93.3%)
CT, computed tomography; FOBT, fecal occult blood test.
aNumbers may not sum to total due to missing data. Percentages were calculated after excluding participants with missing data.
b
“Other” race includes American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander, and mixed race.
c
Reported prior FOBT, colonoscopy, flexible sigmoidoscopy, CT colonography, or double-contrast barium enema.
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Table 2.
Findings in study participants with advanced colorectal neoplasia (N=55)
Type of advanced finding Number with only this type of advanced finding (unless noted)a,b
Any advanced colorectal neoplasiac 55
Invasive carcinomaa 2
Tubular adenoma with size ≥10 mm 36
Sessile serrated polyp with dysplasia 4
Villous adenoma 0
Tubulovillous adenoma 7
Adenoma with high-grade dysplasia 0
Multiple advanced findingsb 6
aOne of the cases with invasive carcinoma also had a villous adenoma.
bCases with multiple findings had:
(a) tubular adenoma with size ≥10 mm and adenoma with high-grade dysplasia (2 cases)
(b) tubular adenoma with size ≥10 mm and tubulovillous adenoma (1 case)
(c) tubular adenoma with size ≥10 mm and sessile serrated adenoma with cytological dysplasia (1 case)
(d) tubulovillous adenoma and adenoma with high-grade dysplasia (2 cases).
cAny of the following colonoscopic findings confirmed by pathology: tubular adenoma with a size of ≥10 mm, sessile serrated polyp with 
dysplasia, villous adenoma, tubulovillous adenoma, adenoma with high grade dysplasia, or invasive carcinoma.
Am J Gastroenterol. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Shapiro et al. Page 15
Ta
bl
e 
3.
Pe
rfo
rm
an
ce
 c
ha
ra
ct
er
ist
ic
s o
f i
m
m
un
oc
he
m
ic
al
 a
nd
 g
ua
ia
c 
fe
ca
l o
cc
ul
t b
lo
od
 te
sts
 fo
r d
et
ec
tio
n 
of
 a
dv
an
ce
d 
co
lo
re
ct
al
 n
eo
pl
as
ia
 (N
=
10
06
)
A
dv
a
n
ce
d 
co
lo
re
ct
al
 n
eo
pl
as
ia
 o
n 
co
lo
no
sc
op
y
Po
sit
iv
ity
 (%
)
Se
ns
iti
v
ity
a
Sp
ec
ifi
ci
ty
a
PP
V
a
Li
ke
lih
oo
d 
ra
tio
a
Ye
s
N
o
(%
)
(95
%
 C
I)b
(%
)
(95
%
 C
I)b
(%
)
(95
%
 C
I)b
(95
%
 C
I)b
St
oo
l t
es
t r
es
ul
t
 
In
Su
re
 F
IT
 
 
Po
sit
iv
e
14
30
4.
5
26
.3
(15
.9–
40
.7)
96
.8
(95
.5–
97
.8)
31
.8
(19
.0–
47
.1)
8.
5
(4.
4–
14
.3)
 
 
N
eg
at
iv
e
39
90
4
 
O
C 
FI
T-
CH
EK
 
 
Po
sit
iv
e
8
20
3.
0
15
.1
(6.
7–
26
.1)
97
.8
(96
.6–
98
.6)
28
.7
(12
.5–
46
.4)
7.
2
(2.
6–
14
.3)
 
 
N
eg
at
iv
e
45
87
4
 
H
em
oc
cu
lt 
II 
SE
N
SA
 
 
Po
sit
iv
e
4
13
1.
7
7.
4
(1.
9–
17
.0)
98
.6
(97
.7–
99
.2)
23
.6
(6.
3–
50
.0)
5.
8
(1.
1–
16
.0)
 
 
N
eg
at
iv
e
51
93
8
D
iff
er
en
ce
 b
etw
ee
n 
tes
t r
es
ul
tsc
 
In
Su
re
 F
IT
–O
C 
FI
T-
CH
EK
11
.2
(0.
4, 
24
.2)
−
1.
0
(−
2.4
, 0
.5)
 
In
Su
re
 F
IT
–H
em
oc
cu
lt 
II 
SE
N
SA
18
.9
(10
.2,
 32
.6)
−
1.
8
(−
3.3
, −
0.7
)
 
O
C 
FI
T-
CH
EK
–H
em
oc
cu
lt 
II 
SE
N
SA
7.
8
(−
1.4
, 1
9.1
)
−
0.
9
(−
2.2
, 0
.3)
CI
, c
on
fid
en
ce
 in
te
rv
al
; P
PV
,
 
po
sit
iv
e 
pr
ed
ic
tiv
e 
v
al
ue
.
a P
oi
nt
 e
sti
m
at
es
 w
er
e 
ba
se
d 
on
 b
ia
s-
co
rre
ct
ed
 e
sti
m
at
es
 fr
om
 2
,0
00
 b
oo
tst
ra
p 
sa
m
pl
es
 d
ra
w
n
 fr
om
 th
e 
or
ig
in
al
 sa
m
pl
e.
b N
in
et
y-
fiv
e 
pe
rc
en
t c
on
fid
en
ce
 in
te
rv
al
s w
er
e 
ca
lc
ul
at
ed
 u
sin
g 
th
e 
ad
jus
ted
 bo
ots
tra
p p
erc
en
tile
 m
eth
od
 (b
ias
-co
rre
cte
d a
nd
 ac
cel
era
ted
).
c D
iff
er
en
ce
 in
 se
ns
iti
v
ity
 o
r s
pe
ci
fic
ity
 b
et
w
ee
n 
th
e 
sto
ol
 te
sts
.
Am J Gastroenterol. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Shapiro et al. Page 16
Ta
bl
e 
4.
Pe
rfo
rm
an
ce
 c
ha
ra
ct
er
ist
ic
s o
f i
m
m
un
oc
he
m
ic
al
 a
nd
 g
ua
ia
c 
fe
ca
l o
cc
ul
t b
lo
od
 te
sts
 fo
r d
et
ec
tio
n 
of
 se
rra
te
d 
le
sio
ns
 (N
=
10
06
)
Se
rr
at
ed
 le
sio
ns
 o
n 
co
lo
no
sc
op
y
Se
ns
iti
v
ity
a
Sp
ec
ifi
ci
ty
a
PP
V
a
Li
ke
lih
oo
d 
ra
tio
a
Ye
s
N
o
(%
)
(95
%
 C
I)b
(%
)
(95
%
 C
I)b
(%
)
(95
%
 C
I)b
(95
%
 C
I)b
St
oo
l t
es
t r
es
ul
t
 
In
Su
re
 F
IT
 
 
Po
sit
iv
e
4
40
5.
2
(1.
4–
12
.9)
95
.6
(94
.1–
96
.8)
9.
1
(2.
3–
22
.5)
1.
2
(0.
3–
3.3
)
 
 
N
eg
at
iv
e
72
87
1
 
O
C 
FI
T-
CH
EK
 
 
Po
sit
iv
e
3
25
4.
2
(1.
2–
11
.4)
97
.1
(95
.9–
98
.1)
10
.9
(0.
0–
27
.8)
1.
5
(0.
3–
4.8
)
 
 
N
eg
at
iv
e
69
85
0
 
H
em
oc
cu
lt 
II 
SE
N
SA
 
 
Po
sit
iv
e
2
15
2.
6
(0.
0–
8.7
)
98
.4
(97
.4–
99
.0)
11
.9
(0.
0–
33
.9)
1.
7
(0.
0–
6.2
)
 
 
N
eg
at
iv
e
76
91
3
D
iff
er
en
ce
 b
etw
ee
n 
tes
t r
es
ul
tsc
 
In
Su
re
 F
IT
–O
C 
FI
T-
CH
EK
1.
0
(−
3.0
, 7
.1)
−
1.
5
(−
3.2
, 0
.1)
 
In
Su
re
 F
IT
–H
em
oc
cu
lt 
II 
SE
N
SA
2.
6
(−
1.4
, 9
.3)
−
2.
8
(−
4.2
, −
1.4
)
 
O
C 
FI
T-
CH
EK
–H
em
oc
cu
lt 
II 
SE
N
SA
1.
6
(−
2.3
, 7
.1)
−
1.
2
(−
2.6
, 0
.1)
CI
, c
on
fid
en
ce
 in
te
rv
al
; P
PV
,
 
po
sit
iv
e 
pr
ed
ic
tiv
e 
v
al
ue
.
a P
oi
nt
 e
sti
m
at
es
 w
er
e 
ba
se
d 
on
 b
ia
s-
co
rre
ct
ed
 e
sti
m
at
es
 fr
om
 2
,0
00
 b
oo
tst
ra
p 
sa
m
pl
es
 d
ra
w
n
 fr
om
 th
e 
or
ig
in
al
 sa
m
pl
e.
b N
in
et
y-
fiv
e 
pe
rc
en
t c
on
fid
en
ce
 in
te
rv
al
s w
er
e 
ca
lc
ul
at
ed
 u
sin
g 
th
e 
ad
jus
ted
 bo
ots
tra
p p
erc
en
tile
 m
eth
od
 (b
ias
-co
rre
cte
d a
nd
 ac
cel
era
ted
).
c D
iff
er
en
ce
 in
 se
ns
iti
v
ity
 o
r s
pe
ci
fic
ity
 b
et
w
ee
n 
th
e 
sto
ol
 te
sts
.
Am J Gastroenterol. Author manuscript; available in PMC 2018 November 01.
